Illumina and Mayo Clinic have reinvested in the genomics services platform, which has closed the first tranche of its series B round.

US-based personal genomics marketplace developer Helix closed the first tranche of a $200m series B round featuring genomics technology provider Illumina and medical research firm Mayo Clinic yesterday.

Growth equity firm DFJ Growth led the tranche, which also included Kleiner Perkins Caufield Byers, Sutter Hill Ventures and Warburg Pincus. The company has not revealed how much it has raised so far but said it expects to close the round at $200m.

Helix launched in 2015 with $100m from Illumina,…